Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17629533 | 0.91 | TRPM2 (0.36) | ALDH1A1PPARGEPHX2KDM4ETRPM2 | |
| SCHEMBL3265220 | 0.87 | LMNA (0.37) | ALDH1A1KDM4EMAPTLTB4R2NPSR1 | |
| SCHEMBL17629556 | 0.82 | PPARG (0.35) | PPARGEPHX2TRPM2NR1H4CETP | |
| SCHEMBL19251713 | 0.80 | TLR2 (0.39) | ALDH1A1PPARGEPHX2KDM4ETRPM2 | |
| SCHEMBL17629564 | 0.76 | PPARG (0.35) | ALDH1A1PPARGEPHX2KDM4ETRPM2 | |
| SCHEMBL19251687 | 0.75 | PPARG (0.38) | ALDH1A1PPARGEPHX2KDM4ETRPM2 | |
| SCHEMBL3776799 | 0.73 | MAPK1 (0.46) | ALDH1A1KDM4EMAPT | |
| SCHEMBL17629562 | 0.72 | CACNA1F (0.36) | ALDH1A1PPARGEPHX2KDM4ETRPM2 | |
| SCHEMBL19251699 | 0.72 | MAPT (0.39) | ALDH1A1KDM4ETRPM2CETPMAPT | |
| SCHEMBL17629493 | 0.70 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3197451-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197455-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049097-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049100-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016045128-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049100-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ALDH1A1 291/4885PPARG 587/4885EPHX2 725/4885 |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, HIF1A, EGLN2 | ALDH1A1 348/4885PPARG 741/4885EPHX2 996/4885 |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ALDH1A1 348/4885PPARG 741/4885EPHX2 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.